Healthcare Sector
Market Tracker
15m Chart - Support and Resistance levels are based on the large dark pool & equity prints at the plotted levels. Displays strongest levels above and below the spot price.
Represents the strikes that had the highest premium of whale flow (on the ASK side) over the past 5 trading days.
Represents the strikes that had the highest premium of whale flow (on the BID side) over the past 5 trading days.
Total Open Interest of Calls & Puts across all strikes and expirations over the past 16 trading days.
| Name | Pct Held | Shares | Total |
|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 0.97% | 275.52k | 89.82k |
| Vanguard Extended Market Index Fund | 0.71% | 203.36k | 66.29k |
| Fidelity Extended Market Index Fund | 0.26% | 73.97k | 24.11k |
| iShares Micro Cap ETF | 0.11% | 32.54k | 10.61k |
| Fidelity Series Total Market Index Fund | 0.08% | 23.94k | 7.8k |
| Fidelity NASDAQ Composite Index Fund | 0.06% | 16.55k | 5.39k |
| Fidelity Total Market Index Fund | 0.04% | 12.77k | 4.16k |
| EQ Advisors Trust-1290 VT Micro Cap Port | 0.01% | 2.34k | 761 |
Adial Pharmaceuticals CEO was a Featured Guest on The Big Biz Show
10/17 09:00 am
GlobeNewswire Inc.
Read moreEvolving Landscape of Mental Health Segment: Key Market Insights of the Latest Published Substance Use Disorders Report — Alcohol Use Disorder, Cocaine Use Disorder, Opioid Use Disorder, and Cannabis Use Disorder | DelveInsight
04/28 01:00 pm
GlobeNewswire Inc.
Read moreAdial Pharmaceuticals Receives Positive Response from FDA Meeting Regarding Proposed In Vitro Bridging Strategy for AD04
02/25 10:00 am
GlobeNewswire Inc.
Read moreAdial Pharmaceuticals Announces Positive Clinical Study Results from the AD04-103 Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder
01/29 10:00 am
GlobeNewswire Inc.
Read moreAlcohol Use Disorder Market Set for Remarkable Growth During the Study Period (2020–2034) | DelveInsight
12/11 02:00 pm
GlobeNewswire Inc.
Read moreEXCLUSIVE: Adial Pharmaceuticals Moves Forward To Second Cohort In Pharmacokinetics Study of AD04 For Alcohol Use Disorder - Benzinga
07/23 08:00 am
Benzinga
Read moreAdial Pharmaceuticals Announces Publication in Leading Peer-Reviewed Journal Supporting the Potential Efficacy of AD04 as a Precision Medicine for the Treatment of Alcohol Use Disorder
06/20 08:30 am
GlobeNewswire Inc.
Read moreAdial Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
05/15 08:30 am
GlobeNewswire Inc.
Read moreAdial Pharmaceuticals Granted Key Patent from the United States Patent and Trademark Office
04/22 08:30 am
GlobeNewswire Inc.
Read moreS&P 500 Down 1%; Delta Air Lines Posts Upbeat Earnings
04/10 02:34 pm
Benzinga
Read moreDow Falls Over 1%; US Inflation Rate Accelerates In March
04/10 10:20 am
Benzinga
Read moreAdial Pharmaceuticals Announces Peer-Reviewed Publication Highlighting Promising Safety Data and High Patient Compliance in a Clinical Trial of AD04 as a Potential Treatment for Alcohol Use Disorder
04/10 08:30 am
GlobeNewswire Inc.
Read moreAdial Pharmaceuticals Reports 2023 Fiscal Year Financial Results and Provides Business Update
04/02 08:30 am
GlobeNewswire Inc.
Read moreIs Masimo (MASI) Outperforming Other Medical Stocks This Year?
03/11 09:40 am
Zacks Investment Research
Read moreFinding Long Term Penny Stocks Investments? 3 Tips
03/04 07:51 am
PennyStocks
Read moreTop Habits Penny Stocks Traders Need to Follow
03/02 07:18 am
PennyStocks
Read moreAdial Pharmaceuticals Announces Exercise of Warrants for $3.5 Million Gross Proceeds
03/01 08:00 pm
GlobeNewswire Inc.
Read moreUS Stocks Mixed; Dell Posts Upbeat Results
03/01 10:47 am
Benzinga
Read moreWhat Trends Are Causing Penny Stocks to Move in 2024?
03/01 07:26 am
PennyStocks
Read moreTips for Understanding Penny Stocks Fundamentals
02/29 07:23 am
PennyStocks
Read moreS&P 500 Edges Lower; ADT Posts Upbeat Earnings
02/28 03:30 pm
Benzinga
Read moreNasdaq Down 50 Points; US Crude Stocks Rise By 4.2M Barrels
02/28 01:25 pm
Benzinga
Read moreDow Dips 200 Points; TJX Posts Upbeat Sales
02/28 11:12 am
Benzinga
Read moreAdial Pharmaceuticals Awarded New Patent from the United States Patent and Trademark Office
02/28 10:30 am
GlobeNewswire Inc.
Read moreAdial Pharmaceuticals Awarded New Patent Notice of Allowance from the United States Patent and Trademark Office
02/13 10:15 am
GlobeNewswire Inc.
Read moreAdial Announces Appointment of Tony Goodman as Chief Operating Officer
01/18 09:30 am
GlobeNewswire Inc.
Read moreAdial Pharmaceuticals Receives Final Reimbursement Payment from Adovate
12/20 10:00 am
GlobeNewswire Inc.
Read moreAdial Pharmaceuticals Regains Compliance with Nasdaq Listing Requirement
11/29 05:05 pm
GlobeNewswire Inc.
Read moreAdial Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update
11/14 06:02 pm
GlobeNewswire Inc.
Read moreAdial Pharmaceuticals Chief Medical Officer and Key Opinion Leaders to Discuss “New Aspects in Substance Use Treatment” at The Annual International Society of Addiction Medicine Conference
10/31 08:30 am
GlobeNewswire Inc.
Read moreAll You Need to Know About Adial Pharmaceuticals, Inc. (ADIL) Rating Upgrade to Buy
10/30 12:00 pm
Zacks Investment Research
Read moreAdial Pharmaceuticals Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
10/24 04:30 pm
GlobeNewswire Inc.
Read moreNasdaq Down Over 1%; Autoliv Raises FY23 Sales Outlook
10/20 02:42 pm
Benzinga
Read moreDow Falls 50 Points; American Express Earnings Top Views
10/20 09:43 am
Benzinga
Read moreAdial Pharmaceuticals Announces $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
10/20 08:00 am
GlobeNewswire Inc.
Read moreAdial Pharmaceuticals Awarded Notice of Allowance for Key Patent Combining Use of the Company’s Proprietary Genetic Diagnostic with AD04 to Treat Alcohol and Drug Dependence
10/19 10:30 am
GlobeNewswire Inc.
Read moreAdial Pharmaceuticals Wins Frost & Sullivan's 2023 North American Precision Medicine for Addiction Disorders Technology Innovation Leadership Award
10/18 08:00 am
GlobeNewswire Inc.
Read more